Table 3.
Clinical Features of PCV Subsequent to Chronic CSC. *Lost of follow-up; F, female; M, male; SFCT, subfoveal choroidal thickness; SRF, subretinal fluid; PDT: photodynamic therapy; VEGF, vascular endothelial growth factor; PCV, polypoidal choroidal vasculopathy.
| Case | Age | Gender | Time to PCV formation (months) | SFCT (μm) | PCV morphology | Treatment | Response |
|---|---|---|---|---|---|---|---|
| 1 | 50 | F | 104 | 306 | PCV type 1 | Anti-VEGF | Resolution |
| 2 | 63 | M | 45 | 163 | PCV type 2 | Anti-VEGF | SRF persisted |
| 3 | 46 | M | 84 | 429 | PCV type 1 | Anti-VEGF | N/A* |
| 4 | 63 | F | 27 | 339 | PCV type 2 | Anti-VEGF | Resolution |
| 5 | 54 | M | 48 | 318 | PCV type 1 | Anti-VEGF | Resolution |
| 6 | 52 | M | 62 | 355 | PCV type 1 | – | |
| 7 | 47 | F | 105 | 287 | PCV type 1 | Anti-VEGF | SRF persisted |
| 8 | 46 | M | 92 | 259 | PCV type 1 | – | |
| 9 | 42 | M | 32 | 246 | PCV type 1 | – | |
| 10 | 57 | M | 108 | 516 | PCV type 1 | Anti-VEGF | Resolution |
| 11 | 42 | M | 65 | 589 | PCV type 2 | Anti-VEGF | SRF persisted |
| 12 | 53 | M | 90 | 599 | PCV type 1 | PDT | Resolution |
| 13 | 49 | M | 72 | 134 | PCV type 1 | Anti-VEGF | Resolution |
| 14 | 42 | M | 98 | 237 | PCV type 2 | PDT + Anti-VEGF | Resolution |
| 15 | 52 | M | 106 | 159 | PCV type 2 | PDT + Anti-VEGF | Resolution |
| 16 | 47 | M | 74 | 184 | PCV type 2 | PDT + Anti-VEGF | Resolution |
| 17 | 62 | M | 82 | 464 | PCV type 2 | PDT + Anti-VEGF | Resolution |
| 18 | 51 | M | 108 | 315 | PCV type 2 | – |